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INTRODUCTION
Spinal muscular atrophy (SMA) is a severe, autosomal recessive 
neuromuscular disease that represents the most common genetic 
cause of infant death, with an incidence of approximately 1 in 
10,000 live births and a carrier frequency of 1 in 40–60.1–3 SMA is 
caused by homozygous loss of the SMN1 telomeric gene function 
by deletion, conversion or mutation, leading to reduced levels of 
the full-length SMN protein.4–6 SMN is ubiquitously expressed and 
involved in multiple aspects of RNA metabolism, including splic-
ing.7–9 SMN deficiency affects multiple tissues and organs at variable 
extent, although the neuronal tissue is invariably affected resulting 
in α-motor neuron degeneration in the spinal cord with subsequent 
neuromuscular junction dysfunction and proximal muscle weak-
ness.10,11 The human genome contains a centromeric SMN2 gene, a 
highly homologous version of SMN1 which differs in a translation-
ally silent C to T transition in exon 7 (ref. 5). The mutation disrupts an 
exonic splicing enhancer and results in enhanced skipping of exon 7 
and synthesis of only 10% of full-length transcripts.12 The truncated 
SMNΔ7 protein is highly unstable and rapidly degraded. In general, 
the SMN2 copy number—and thus the total amount of full-length 
SMN—is inversely correlated with the severity of the disease.13–15
SMA is generally classified into five clinical variants (type 0 to 4) 
according to age of onset and severity of symptoms.16 Type-1 SMA 
accounts for ~50% of all patients, affects infants under 6 months 
of age and is lethal within the first 2 years of life.17 A fundamental 
strategy for treating SMA is to increase SMN levels in the affected 
tissues: this has been attempted by modulating SMN2 exon 7 splic-
ing, by increasing SMN2 transcriptional levels, or by SMN1 gene 
replacement with recombinant adeno-associated viral (AAV) vec-
tors.18–22 We and others previously reported that intravenous (IV) 
administration of a self-complementary, serotype-9 (scAAV9) vec-
tor expressing a human SMN1 cDNA gene rescues the phenotype 
of SMNΔ7 mice, a severe animal model of the disease.23–27 AAV9 
vectors are able to cross the blood–brain barrier (BBB) and mediate 
transgene expression in the central nervous system (CNS) in rodents 
and larger animals.28–32 However, since high doses of vector are 
required to deliver efficaciously a transgene to the CNS by IV injec-
tions and a transient hepatitis that is controlled by a short course of 
Received 26 April 2016; accepted 15 July 2016
2329-0501
16060








Official journal of the American Society of Gene & Cell Therapy
Efficacy and biodistribution of scAAV9-SMN1 by ICV administration in SMNΔ7 mice
N Armbruster et al.
Spinal muscular atrophy (SMA) is an autosomal recessive disease of variable severity caused by mutations in the SMN1 gene. Defi-
ciency of the ubiquitous SMN function results in spinal cord α-motor neuron degeneration and proximal muscle weakness. Gene 
replacement therapy with recombinant adeno-associated viral (AAV) vectors showed therapeutic efficacy in several animal models 
of SMA. Here, we report a study aimed at analyzing the efficacy and biodistribution of a serotype-9, self-complementary AAV vector 
expressing a codon-optimized human SMN1 coding sequence (coSMN1) under the control of the constitutive phosphoglycerate 
kinase (PGK) promoter in neonatal SMNΔ7 mice, a severe animal model of the disease. We administered the scAAV9-coSMN1 vector 
in the intracerebroventricular (ICV) space in a dose-escalating mode, and analyzed survival, vector biodistribution and SMN protein 
expression in the spinal cord and peripheral tissues. All treated mice showed a significant, dose-dependent rescue of lifespan and 
growth with a median survival of 346 days. Additional administration of vector by an intravenous route (ICV+IV) did not improve 
survival, and vector biodistribution analysis 90 days postinjection indicated that diffusion from the cerebrospinal fluid to the 
periphery was sufficient to rescue the SMA phenotype. These results support the preclinical development of SMN1 gene therapy by 
CSF vector delivery.
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glucocorticoid therapy has been associated to this route of adminis-
tration,33,34 other delivery modes have been investigated in preclini-
cal models, such as the intramuscular, intracerebroventricular (ICV) 
and combined ICV and intrathecal delivery.27,35,36 In particular, one 
study showed that administration of an AAV9 vector directly in the 
cerebrospinal fluid (CSF) leads to rapid and long lasting correction 
of SMN levels and phenotypic rescue of SMNΔ7 mice at lower vector 
doses compared to a systemic administration.37
In this study, we investigated the therapeutic efficacy of adminis-
tering a scAAV9 vector expressing a codon-optimized (co) version of 
the human SMN1 cDNA under the control of the phosphoglyceroki-
nase (PGK) promoter (scAAV9.PGKcoSMN1) in the ICV space in neo-
natal SMNΔ7 mice. We show prolonged and robust correction of the 
SMA phenotype at a dose of 4 × 1010 vg/mouse (3 × 1013 vg/kg), with 
median and maximum survival of 346 and 406 days respectively, 
the longest reported so far in this animal model. Vector and protein 
biodistribution analysis showed robust transduction of the CNS and 
expression of SMN1 at substantial levels in liver, skeletal muscles, 
and heart. IV administration of different doses of the same vector in 
combination with ICV administration led to a significant increase of 
genome and protein levels in the peripheral organs but not in the 
CNS, did not prolong survival and provided no obvious additional 
benefit. This study therefore supports the concept that CSF delivery 
of an AAV vector could be sufficient to treat SMA patients.
ReSUlTS
ICV administration of AAV9-SMN1 increases survival and rescues the 
SMA phenotype of SMNΔ7 mice
The scAAV9-coSMN1 vector used in this study contains a codon-
optimized human SMN1 coding sequence and a chimeric intron 
under the control of the constitutive PGK promoter, as previously 
described.24 Systemic, IV delivery of this vector (referred hereafter as 
AAV9-SMN1) at a dose of 4.5 × 1010 vg/mouse showed therapeutic 
efficacy in the SMNΔ7 mouse model of severe SMA.24 In the pres-
ent study, we aimed at testing the efficacy of ICV administration of 
the vector in the same animal model, by injecting escalating doses 
of AAV9-SMN1 (2.5 × 1010, 4 × 1010, and 1011 vg/mouse) into the ICV 
space at birth (PND0) in 16 mice per group (Table 1). As shown in 
Figure 1a, the lowest dose of AAV9-SMN1 was already sufficient to 
prolong the survival of SMNΔ7 mice from <14 days to up to 1 year 
(median survival: 201 days). The intermediate dose, correspond-
ing to 3 × 1013 vg/kg (weight of SMNΔ7 mice at PND0: 1.34 ± 0.18 g, 
n = 16) provided the longest, statistically significant median survival 
of 346 days (Mantel-Cox log-rank test, P-value = 0.0032). The first 
death within this group occurred at day 208 and the longest sur-
vival was 406 days. The group of mice treated at the highest dose, 
corresponding to 7.5 × 1013 vg/kg, showed a higher degree of early 
mortality compared to the other groups, with half of the mice dying 
before 3 months of age and an overall median survival of 154 days. 
However, mice surviving over 3 months exhibited a median survival 
of 284 days and the highest observed survival, with a mouse eutha-
nized at the end of the study at the age of 510 days (Figure 1a).
A second cohort of mice received at birth a constant ICV dose 
of 2 × 1010 vg/mouse combined with three different doses (5 × 109, 
2 × 1010, and 8 × 1010 vg/mouse) delivered IV, corresponding to an 
ICV:IV ratio of 0.25, 1, and 4. The median survival observed in the 
three groups was 283, 188, and 262 days, a statistically nonsignifi-
cant difference with respect to the 201 median survival of mice 
receiving an ICV only dose of 2.5 × 1010 vg/mouse (Mantel-Cox log-
rank test, P-value = 0.346) (Figure 1b). Of note, we observed a sta-
tistically significant higher median survival in mice receiving an ICV 
dose of 4 × 1010 vg/mouse (346 days, Figure 1a) compared to mice 
receiving the same dose split 1:1 by ICV+IV administration (188 
days, ratio 1 in Figure 1b) (Mantel-Cox log-rank test, P = 0.023).
We then assessed the effect of AAV9-SMN1 administration on the 
growth of SMNΔ7 mice, which undergo a significant loss of weight 
starting around day 9 when untreated (3.3 ± 0.9 g at PND9 versus 
6.1 ± 1 g in WT controls), and die before day 14 (Figure 1c). All treated 
mice showed a progressive increase in body weight reaching a 
plateau around 110 days, with no significant differences between 
groups, with the exception of mice treated at 1 × 1011 vg/mouse 
that lost weight between day 28 and 50 compared to the other 
treated animals (P < 0.05) due to the mice that died early. Mice sur-
viving beyond day 50 showed no significant difference in growth 
compared to the other mice (Figure 1c). Overall, all treated mice 
remained smaller than WT control animals.
Biodistribution of AAV9-SMN1 in SMNΔ7 mice after ICV and ICV+IV 
administration
We analyzed the biodistribution of AAV9-SMN1 by quantifying the 
vector copy number (VCN) in the spinal cord and peripheral tissues in 
separate cohorts of SMNΔ7 mice injected at birth ICV or ICV+IV and 
sacrificed 90 days postinjection (Figure 2). Primers and probes were 
specifically designed to distinguish the codon-optimized human 
SMN1 transgene from the hSMN2 sequences introduced in the 
SMNΔ7 mouse genome. Mice that received ICV injections at a dose 
of 4 × 1010 vg/mouse showed a high VCN in the spinal cord (6.9 ± 1.3 
vector copies per diploid genome, vg/dg) and a comparable amount 
of vector in the liver (Figure 2a,b). The liver tropism of AAV9 in mice is 
known and was in line with previous reports.38,39 The group of mice 
Table 1 Study design and overview of the different animal 
cohorts included in the study 
ICV delivery:
N (mice) ICV  
(vg/mouse)












Total dose in (vg/kg)
16 2E10 5E9 0.25 1.9E13
16 2E10 2E10 1 3.0E13
16 2E10 8E10 4 7.5E+13
The doses of AAV9-SMN1 administered in the various experimental groups 
are reported and expressed as total vg/mouse, and for better comparison 
as vg/kg on the right side of the table. The ICV+IV delivery groups received 
beside the constant ICV dose, a systemic injection through the facial vein; the 
Ratio indicates the proportion between vector doses administered through 
the two delivery routes. Mice (n=8 per group) were euthanized at postnatal 
day 90 (PND90) and organs were harvested for the biodistribution study. The 
other half number of mice per group was used for the survival study (n=8, 
with equally males and females). The same number of uninjected WT and KO 
sex-matched littermates was used as controls respectively.
ICV, intracerebroventricular.
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that received a dose of 2.5 × 1010 vg/mouse showed a lower VCN in 
the spinal cord (2.4 ± 1 vg/dg). Both groups showed a low VCN in heart 
(1.8 ± 0.5, Figure 2c) and in the Tibialis anterior (TA) and Gastrocnemius 
(GA) skeletal muscles (TA: 0.2 ± 0.1; GA: 0.1 ± 0.02, Figure 2d,e). In mice 
treated at the highest dose of 1011 vg/mouse that survived until 90 
days postinjection, we found a VCN in spinal cord and liver compa-
rable to the intermediate dose group (Figure 2a,b) but a significantly 
higher vector accumulation in skeletal muscles and particularly in the 
heart (17.3 ± 9.4 vg/dg) (Figure 2c–e), likely due to a significant pas-
sage of vector toward the peripheral organs.
We then assessed vector distribution in the ICV+IV cohorts: VCN 
in the spinal cord remained constant at increasing IV doses from 
5 × 109 to 8 × 1010 vg/mouse (1.4 ± 0.2, 1.3 ± 0.2, and 1.6 ± 0.3 vg/
dg, respectively), at levels comparable to those observed in mice 
injected ICV only at a dose of 2.5 × 1010 vg/mouse (2.3 ± 1 vg/dg), 
while VCN in liver and heart increased with the IV vector dose, up 
to >15 and >9 vg/dg respectively (Figure 2a–c). These data suggest 
that CNS transduction is achieved essentially by the vector deliv-
ered ICV, while vector delivered IV transduces mainly the peripheral 
organs, and particularly liver and heart. Only the highest IV dose 
(8 × 1010 vg/mouse, ratio 4) resulted in a significant increase in vec-
tor copies in skeletal muscles (TA: 1.6 ± 0.5 vg/dg; GA: 0.7 ± 0.2), indi-
cating a lower tropism of AAV9 for this tissue in newborn mice.
Synthesis of SMN protein in the spinal cord and peripheral organs 
of treated SMNΔ7 mice
We analyzed the level of SMN protein in various tissues of SMNΔ7 
mice 3 months after AAV9-SMN1 administration by western blot-
ting. Densitometry data were normalized against the expression 
Figure 1  Effect of single ICV and ICV+IV combined injections of AAV9-SMN1 in SMNΔ7 mice. Kaplan-Meier survival curves (a, b): all AAV9-SMN1 doses 
prolonged lifespan. (a) Intracerebroventricular (ICV) injection of AAV9-SMN1 at various doses (2.5E10 vg, 4E10 vg, and 1E11 vg/mouse) in newborn 
SMNΔ7 mice. The median survival is given as number next to each curve (n = 8 per group). (b) Combination of ICV (2E10 vg/mouse) and intravenous 
(IV) vector administration at various ratios (ratio 0.25: 5E9 vg IV + 2E10 vg ICV/mouse, ratio 1: 2E10 vg IV + 2E10 vg ICV/mouse, and ratio 4: 8E10 vg IV + 
2E10 vg ICV/mouse). The median survival is given as a number next to each curve (n = 8 per group). Untreated WT (n = 8) and KO mice (n = 8) were used 
as controls, and groups were compared using the log-rank test in a and b. (c) Body weight of untreated and treated SMNΔ7 mice with AAV9-SMN1 (ICV 
and ICV+IV at various doses) (n = 16 mice per group until day 90, which includes n = 8 mice/group from the biodistribution study, and thereafter “n” 
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of a constitutive protein (tubulin) and expressed as SMN/Tubulin 
ratios. Mice in the group with the highest median survival (ICV 
administration, 4 × 1010 vg/mouse) and two ICV+IV groups (ratio 
1 and ratio 4) were compared to aged-matched WT mice and to 
untreated SMNΔ7 littermates at the age of 14 days. SMN expression 
data were in line with vector biodistribution in the same groups of 
mice. Mice in all groups had similar levels of SMN expression in the 
spinal cord, reaching >50% of the WT values, indicating significant 
restoration of overall protein levels and confirming that IV delivery 
has no major impact in transducing the spinal cord (Figure 3a). Mice 
in the ICV+IV ratio 4 group showed the highest amount of SMN pro-
tein in peripheral organs (Figure 3b–e), reaching endogenous SMN 
levels in the heart (Figure 3c).
We further investigated SMN protein expression by immunohis-
tochemistry in a separate group of mice treated ICV with the dose 
that allowed for the longest survival in the long-term study (4 × 1010 
vg/mouse). Mice were euthanized 3 months post-injection together 
with age-matched WT controls and untreated SMNΔ7 mice. The 
lumbar SC was cryostat-cut and processed for immunohistochem-
istry. The staining revealed robust SMN expression in the lumbar 
spinal cord of WT mice with an intense staining in α-motor neurons 
(Figure 3g). On the contrary, the SMN signal was very low and scat-
tered in the same region of untreated SMN∆7 mice. We detected a 
significant recovery of SMN expression, with the typical staining in 
α-motor neurons, in the lumbar spinal cord of mice treated with the 
AAV9-SMN1 vector (Figure 3g).
DISCUSSION
SMA is caused by partial or complete loss of the SMN1 gene function 
and is classified in five clinical variants of increasing severity depend-
ing on the level of residual, ubiquitous SMN protein. Past attempts 
to treat murine models of SMA by gene replacement therapy have 
shown very significant results in terms of efficacy. Administration 
of AAV vectors expressing the human SMN protein caused partial 
rescue of the SMA phenotype and significant prolongation of sur-
vival in the SMNΔ7 severe mouse model.24–26,36,37 However, because 
of differences in the delivery route, dosage, age at injection, viral 
vector serotype, and transgene expression cassette, these stud-
ies are difficult to compare and defining the best strategy to treat 
this disease remains challenging. Nevertheless, on the basis of the 
promising results obtained by systemic IV delivery, a phase 1/2 clini-
cal trial started in 2014 at Nationwide Children’s Hospital (Ohio State 
University, Columbus USA; trial ID: NCT02122952), with the aim of 
proving safety and efficacy of gene therapy by intravascular admin-
istration of a scAAV9 vector expressing the human SMN1 transgene.
The SMA disease is considered to be primarily related to lower 
motor neuron loss in the spinal cord. However, whether target-
ing motor neurons only would be sufficient to treat the disease, 
Figure 2 AAV9-SMN1 vector biodistribution 3 months after injection. (a–e) Vector copy number (VCN), which corresponds to viral genomes/diploid 
genome (vg/dg), was quantified in various tissues (thoracic part of the spinal cord, liver, heart, tibialis anterior, and gastrocnemius muscles) of mutant 
SMNΔ7 mice 90 days post-injection. Mice received the vector at different doses by intracerebroventricular injection alone (ICV, 2.5E10 vg, 4E10 vg and 
1E11 vg /mouse) and in combination with intravenous (IV) delivery at various ratios (ratio 0.25: 5E9 vg IV + 2E10 vg ICV/mouse, ratio 1: 2E10 vg IV + 
2E10 vg ICV/mouse, and ratio 4: 8E10 vg IV + 2E10 vg ICV/mouse) (n = 8 for each group, with exception of the group treated by ICV at 1E11 vg/mouse, 
n = 3). Tissues from untreated WT (n = 8) and KO mice (n = 3) were used as negative controls (undetectable, data not shown). VCN with values <0.0005 
were considered as undetectable. Spinal cord: one-way ANOVA; liver, heart, tibialis anterior, and gastrocnemius muscles: two-way analysis of variance 
and Bonferroni post-test; *P < 0.05, **P < 0.01, ***P < 0.001.
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particularly in type-I patients presenting associated pathologies 
unrelated to the nervous system,40–42 is a highly controversial issue. 
In particular, the question of whether transduction of peripheral tis-
sues, such as skeletal muscles and heart, would be necessary for all 
patients and all clinical variants is of high importance.40,42–47 Several 
studies have suggested that SMN expression in muscles might be 
advantageous,48–52 although SMN restoration in skeletal muscles 
alone did not rescue the SMA phenotype in transgenic mice.53 A 
recent report showed that SMN reduction solely in skeletal muscles 
had no phenotypic effect in SMA mice carrying two SMN2 copies, 
strongly suggesting that low SMN levels might be sufficient for a 
normal muscle function in moderately severe SMA patients.46 In 
this study, we show that ICV delivery of scAAV9-SMN1 is sufficient 
in rescuing the phenotype of severely affected SMNΔ7 mice and 
provide substantial levels of SMN also to peripheral organs, while 
no significant additional benefit was observed by combining an IV 
Figure 3 SMN protein localization in the spinal cord three months after vector administration in SMNΔ7 mice. (a–e) Intracerebroventricular-only delivery 
provided a higher amount of SMN protein in the lumbar part of the SC (shown in red, 4E10 vg/mouse). With the highest given IV dose (ratio 4) more 
SMN protein was detected in the heart and TA muscle. SMN levels were normalized to the loading control (α-tubulin) and the WT controls (set as 1). (f) 
Exemplary western blot analysis of spinal cord samples. 30 µg protein lysates were loaded (except for the muscles: 60 µg), n = 8 for each group. Spinal 
cord: one-way analysis of variance (ANOVA), liver, heart, tibialis anterior, and gastrocnemius muscles: two-way ANOVA and Bonferroni post-test; *P < 
0.05, **P < 0.01, ***P < 0.001. (g) Immunohistochemistry for SMN protein in the anterior horn of the lumbar spinal cord. Pictures from untreated SMNΔ7 
WT (left), KO (middle), and AAV9-SMN1 treated KO (right) mice are shown (AxioSCAN microscope). Scale bar, 200 µm. Insets show α-motor neurons at 
higher magnification.
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coadministration that further increased SMN expression in muscle 
and heart. ICV delivery of the scAAV9-SMN1 vector at an optimal 
dose of 3 × 1013 vg/kg in newborn SMNΔ7 mice led to a complete 
rescue of the disease-associated perinatal mortality and a signifi-
cant recovery of the clinical symptoms, with the longest median 
and maximal survival reported so far in this animal model, i.e., 346 
and 406 days. These results were obtained with an average of 7 vec-
tor copies per diploid genome in the spinal cord measured 90 days 
postinjection, which led to synthesis of SMN protein in the CNS at 
levels comparable to those observed in WT animals. Previous stud-
ies using the same vector delivered IV or IM resulted in a median 
lifespan of 163 and 199 days, respectively,24,35 while ICV delivery 
of a similar vector, scAAV9.CBA.SMN, achieved a maximal survival 
of 282 days.37 Delivery of a higher vector dose, up to 7.5 × 1013  
vg/kg allowed to achieve a longer survival in 30% of the mice, up to 
more than 500 days. Some degree of early mortality was observed 
in some groups of treated mice, and was more pronounced in the 
group of animals given the highest vector dose. We could not deter-
mine the cause of death in these animals, which may be related to 
variabilities in vector response, or other factors associated to the 
procedure.
It is well established that serotype-9 AAV vectors can cross the 
BBB when administrated either intravenously or into the CSF.28,30,54 
Accordingly, we found significant VCNs of AAV9-SMN1 in liver, heart, 
and two types of skeletal muscles 90 days after ICV delivery, with 
SMN protein levels reaching 25 to 50% of the normal levels in these 
organs. These levels were apparently sufficient to correct the dis-
ease phenotype in the whole body. In fact, splitting the efficacious 
dose of 4 × 1010 vg/mouse in a combined ICV+IV delivery in a 1:1 
ratio reduced the median survival to 188 days, compared to the 346 
days obtained by the full dose administrated ICV only. Raising the 
IV dose up to 8 × 1010 vg/mouse (IV:ICV ratio of 4:1) increased the 
survival to a median of 262 days but was still less efficacious than a 
unique dose of 4 × 1010 vg administrated ICV. Increasing the IV dose 
caused no augmentation of vector and protein levels in the CNS, 
while it increased significantly the vector load in the liver and heart, 
two organs targeted at high efficiency in the mouse by an AAV9 vec-
tor. These results clearly support the CSF administration as a deliv-
ery route for gene therapy of SMA by a scAAV9 vector. This is par-
ticularly plausible for type 2 to 4 SMA patients in whom peripheral 
abnormalities are uncommon,55,56 and given the results on vector 
biodistribution, it could be beneficial even for type 1 patients that 
manifest additional cardiac and/or vascular defects.44,57,58 A recent 
study in a large animal model of SMA supports these conclusions 
and confirms the therapeutic benefit of administering an AAV9 vec-
tor directly in the CSF. Knock-down of SMN obtained by intrathecal 
delivery of a scAAV9-shRNA vector targeting the SMN1 gene in new-
born pigs resulted in a SMA phenotype, with loss of spinal motor 
neurons and proximal muscle weakness.59 Restoration of SMN levels 
and a striking phenotype correction were observed after pre- and 
postsymptomatic delivery of a scAAV9-SMN vector in the cisterna 
magna of these animals.59 The impressive phenotype amelioration 
after disease onset is highly encouraging, as it widens the therapeu-
tic window of AAV-mediated gene therapy beyond the evidence 
obtained in the mouse model.32,60
Additional advantages of administering an AAV vector directly 
into the CSF are related to potential immune responses. In humans, 
anti-AAV antibody titers are lower in CSF than in serum, and it has 
been reported that high serum levels of anti-AAV9 antibodies only 
partially blocks CSF-mediated gene transfer to the brain in dogs.54 
This and previous studies predict that a lower vector dose may 
be required to achieve a therapeutic effect when an AAV vector is 
administrated in the CSF as compared to an IV route, with a conse-
quent reduction of the predicted T-cell-mediated liver toxicity and 
a reduced need for steroid treatment or immune suppression.34,37,61
MATeRIAlS AND MeTHODS
Generation of recombinant scAAV9-coSMN1 vectors
The human SMN1 AAV2 plasmid has been described previously.24 Briefly, it 
contains the inverted terminal repeat of AAV2, a codon-optimized version 
of the human SMN1 coding sequence under the control of the human PGK 
promoter, a chimeric intron and a SV40 polyadenylation signal. Adenovirus-
free pseudotyped rAAV2/9 vector preparations were generated by triple 
transfection of HEK293 cells with the plasmids pSMNopti, pXX6 encoding 
adenovirus helper functions and p5E18-VD2/9 that contains the AAV2 rep 
and AAV9 cap genes. Recombinant vectors were purified by double cesium 
chloride ultracentrifugation gradients from cell lysates, followed by dialysis 
against sterile formulation buffer PBS-MK (1 mmol/l MgCl2- 2.5 mmol/l KCl). 
The viral preparations were desalted and concentrated using Amicon Ultra 
columns (Ultra cell 100 K; Milipore, France). Physical particles were quantified 
by real-time polymerase chain reaction (PCR) and vector titers are expressed 
as viral genomes per ml (vg/ml). The pseudotyped packaged vector was des-
ignated scAAV9-coSMN1 (lots: T12079.VEC; T12080.VEC).
Animals
SMNΔ7 founder mice were purchased from Jackson (stock number: 5025). 
Beside the disruption of exon2 of the endogenous mouse Smn gene, these 
mice harbor two transgenic alleles, the entire human SMN2 gene and a SMN1 
cDNA lacking exon 7 (SMNΔ7). WT mice corresponded to Smn+/+, SMN2+/+, 
SMNΔ7+/+, heterozygous to Smn+/-, SMN2+/+, SMNΔ7+/+ and knockout 
mice to Smn-/-, SMN2+/+, SMNΔ7+/+. Heterozygous breeding pairs were 
mated and litters were genotyped at birth. Mice were kept under a 12-hour 
light 12-hour dark cycle and fed with a standard diet, with food and water 
ad libitum. Care and manipulation of mice were performed in accordance 
with national and European legislations on animal experimentation and 
approved by the institutional ethical committee.
Vector administration
The study was performed with two scAAV9-coSMN1 production batches 
with a titer of 1.8 × 1013 and 1.6 × 1013 viral genomes per ml (vg/ml) respec-
tively. The vectors were diluted accordingly to the treatment group with 
saline and injections were performed at the day of birth after genotyping. 
A mounted Hamilton glass micropipette (connected to a 32 G needle; both: 
NH BIO, France) was used to slowly inject (2–3 seconds) the vector into the 
lateral ventricle of the right cerebral hemisphere (ICV injection volume: 7 µl). 
For the systemic delivery, a volume of 30 µl was injected into the facial vein. 
Noninjected WT or SMNΔ7 littermates were used as controls.
Tissue sampling
Tissues were collected 90 days postinjection for VCN and SMN protein analy-
sis. Mice were deeply anesthetized by intraperitoneal injection of 100 mg/kg 
ketamine 500 (50 mg/ml, Virbac, France) and 10 mg/kg xylazine (2 %, Rompun, 
Bayer, France) and intracardially perfused with phosphate buffer solution 
(PBS) via the left ventricle. The spinal cord (cervical, thoracic, and lumbar parts), 
heart, gastrocnemius (GA) and tibialis anterior (TA) muscles (the left and right 
muscles were used for protein and gDNA extraction, respectively) and liver 
were harvested and immediately flash-frozen in liquid nitrogen.
Immunohistochemistry
Mice dedicated to immunohistochemistry received subcutaneously 0.1 mg/
kg buprenorphine (Buprecare, 0.3 mg/ml, Axience, France) and were deeply 
anesthetized by intraperitoneal injection of 100 mg/kg ketamine 500 (50 mg/
ml, Virbac, France) and 10 mg/kg xylazine (2%, Rompun, Bayer, France) and 
intracardially perfused via the left ventricle with PBS followed by 4% para-
formaldehyde. Neural tissues (brain and spinal cord) were postfixated for 
24 hours in 4% paraformaldehyde (PFA), equilibrated for 24 hours in 30% 
sucrose in PBS and quickly frozen in 7.5% gelatine or OCT (CML, France) by 
using isopentane cooled in dry ice. Serial coronal cryostat (12–14 μm-thick) sec-
tions were collected and processed for anti-SMN staining (anti-SMN primary 
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antibody, goat polyclonal Santa Cruz, sc-7804). After a heat-induced epitope 
retrieval step, with an incubation of the sections for 5 minutes (microwave, 
700W) in citrate buffer (DAKO S1699, unmasking solution pH6, 1/10 diluted 
in distilled water), the sections were subsequently incubated with blocking 
solution (10% Normal Rabbit Serum (DAKO X0902) + 0.3% Triton X-100 in PBS) 
for 1 hour at RT and then incubated overnight at 4 °C with primary antibody 
diluted 1/600 in blocking solution (1/100 Normal Rabbit Serum, Dako X0902, 
France). After thorough washing (PBS, 3 × 5 minutes each), antibody staining 
was revealed using species-specific  horseradish peroxidase (HRP)-conjugated 
secondary antibodies diluted in PBS (rabbit anti-goat HRP, DAKO P0449, 
Dilution: 1/200, 1 hour, RT). Sections were washed in PBS (3 × 5 minutes each), 
and the substrate, DAB+ (3,3’ diaminobenzidine, DAKO K3468, France), was 
applied for 5 minutes to reveal the staining, followed by a washing step in PBS. 
Tissue sections were dehydrated and mounted with permanent mounting 
media (Coverquick 4000, VWR, France) and images were taken using a digital 
slide scanner microscope (Axio Scan Z1, Zeiss).
Western blot analysis
Tissues were weighed and homogenized in lysis buffer (10 mmol/l Tris-HCl 
pH7.4, 1 mmol/l EDTA, 1 mmol/l EGTA, 150 mmol/l NaCl, 4 mmol/l sodium 
pyrophosphate, 100 mmol/l NaF, 2 mmol/l Na3VO4, 0.5% IGEPAL, 1% Triton-X 
100 and protease inhibitors (Complete Mini; Roche Diagnostics, France) using 
MP FastPrep-24 tubes and a Polytron homogenizer (MP Biomedicals, France). 
After centrifugation (2,600 g, 4 °C, 10 minutes) the supernatant was recov-
ered and kept on ice for 30 minutes with occasionally vortexing. Lysates were 
cleared (12,000 g, 4 °C, 20 minutes) and proteins were quantified with the 
Biorad Protein Assay detection kit (Bio-Rad, France). Equal amounts of protein 
(30 µg of total protein for lumbar part of the SC, liver and heart samples and 
60 µg for the GA and TA muscle samples) were loaded on 10 % Mini-Protean 
TGX precast gels (Biorad, France) and transferred to nitrocellulose membranes 
(0.2 µm; Life Technologies-Invitrogen, France). Membranes were incubated 
with Ponceau S staining solution (0.1% (w/v) Ponceau S in 5% (v/v) acetic acid) 
and cut for separate probing with the anti-SMN and loading control antibody. 
After blocking for 1 hour at room temperature with the Odyssey blocking 
buffer (Li-Cor), the membranes were probed overnight with a specific mono-
clonal anti-SMN antibody (BD #610646, dilution: 1/4,000) and anti-αTubulin 
antibody respectively (Santa Cruz sc-5286, Dilution: 1/1,000). Secondary anti-
bodies were incubated for 90 minutes at room temperature (IR Dye 680 Goat 
anti-mouse, A21058 Invitrogen, dilution: 1/10,000). All antibodies were diluted 
in Dulbecco’s phosphate-buffered saline (DPBS)/Odyssey blocking buffer 
(1/1 dilution). The immunoreaction was visualized and quantified using the 
Odyssey Infrared Imager (LI-COR Biotechnology).
Genomic DNA extraction and vector copy number analysis
Tissues were weighed (~20–100 mg) and homogenized in 500–700 µl 
lysis buffer from the Puregene Blood Core kit (Qiagen, France) using MP 
FastPrep-24 tubes and a Polytron homogenizer (MP Biomedicals, France). 
After a centrifugation step (2,600 g, 4 °C, 10 min) the supernatant was recov-
ered, 30 µl Puregene Proteinase K (10 mg/ml) was added following overnight 
incubation under rotation at 55 °C. The genomic DNA (gDNA) was isolated 
according to the manufacturer’s protocol (Puregene Blood Core kit, Qiagen, 
France), quantified using a Nanodrop ND-8000 spectrophotometer (Thermo 
Scientific, France) and stored at 4 °C.
Vector copies per diploid genome were quantified by TaqMan analy-
sis, starting from 100 ng mouse gDNA by amplifying the codon-optimized 
human SMN1 transgene and Ttn as a mouse housekeeping gene. The abso-
lute amount of each gene was obtained by referring to a standard curve 
consisting of a 10-fold serial dilution of a plasmid containing one copy of the 
codon-optimized human SMN1 and Ttn gene (six concentrations, ranging 
from 10–106 copies). The absolute number of vector copies is given as VCN 
(coSMN1) per diploid genome and was obtained by dividing the coSMN1 
amount by half of the Ttn amount. The real-time PCR reactions were run in 
simplex with an ABI Prism 7900 HT SDS v2.3 system (Applied Biosystems). 
Serial dilutions of the plasmid or 100 ng/10 µl mouse genomic DNA were 
included in a mix containing the absolute QPCR Rox mix (Thermo Scientific, 
France), 0.3 µmol/l of specific primers, 0.2 µmol/l of the corresponding TaqMan 
probe and water to a final volume of 25 µl. The run conditions were as fol-
lows: 10 minutes 95°C polymerase activation step, followed by 40 cycles of 
a two-step qPCR (15 seconds of 95 °C denaturation, 1 minute of 60 °C com-
bined annealing/extension). Primers and probes (5’-3’) were used as follows: 
opSMN1-F: TGCTCCTCCCGGTTTCC, coSMN1-R: CGCGAGCATCGACTTCAAG, 
coSMN1 probe: AGCCGGTGTAAACCACCACACAAGTCTC [5’] VIC [3’] TAMRA. 
Ttn-F: AAAACGAGCAGTGACGTGAGC, Ttn-R: TTCAGTCATGCTGCTAGCGC, Ttn 
probe: TGCACGGAAGCGTCTCGTCTCAGTC [5’] FAM [3’] TAMRA.
Statistical analysis
Data were analyzed with Graphpad Prism version 5 (Graphpad Software) 
and expressed as mean ± standard error of the mean (with n = 8, if not other-
wise stated). Statistical differences between mean values were tested using 
one-way analysis of variance and two-way analysis of variance followed by 
a Bonferroni correction for false discovery rate where appropriate. From the 
survival data Kaplan–Meier curves were generated and tested using the 
Mantel–Cox log-rank test. Differences between values were considered to 
be significant with: *P < 0.05, **P < 0.01, ***P < 0.001.
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